Literature DB >> 9003339

Classification of choroidal neovascularization by digital indocyanine green videoangiography.

D R Guyer1, L A Yannuzzi, J S Slakter, J A Sorenson, P Hanutsaha, R F Spaide, S G Schwartz, J M Hirschfeld, D A Orlock.   

Abstract

PURPOSE: The majority of patients with exudative maculopathy due to age-related macular degeneration present with poorly defined or occult choroidal neovascularization (CNV) that cannot be imaged adequately by fluorescein angiography. Digital indocyanine green (ICG) videoangiography is a new technique that allows enhanced imaging of these poorly defined or occult vessels. The authors studied 1000 consecutive cases of occult CNV using digital ICG angiography to describe the various types of neovascularization observed by this technique and to determine the frequency and natural history of the various lesions.
MATERIALS AND METHODS: Digital ICG videoangiography was performed as described previously on 1000 consecutive eyes with occult CNV by fluorescein angiography.
RESULTS: One thousand consecutive eyes with occult CNV by fluorescein angiography were imaged using digital ICG videoangiography. Three morphologic types of CNV were noted by ICG videoangiography, which included focal spots, plaques (well-defined or poorly defined), and combination lesions (in which both focal spots and plaques are noted). Combination lesions can be subdivided into marginal spots (focal spots at the edge of plaques of neovascularization), overlying spots (hot spots overlying plaques of neovascularization), or remote spots (a focal spot remote from a plaque of neovascularization). The relative frequency of these lesions was as follows: there were 283 cases (29%) of focal spots; 597 cases (61%) of plaques, consisting of 265 cases (27%) of well-defined plaques and 332 cases (34%) of poorly defined plaques; and 84 cases (8%) of combination lesions, consisting of 35 cases (3%) of marginal spots, 37 cases (4%) of overlying spots, and 12 cases (1%) of remote spots. In seven additional cases (1%), a mixture of the above lesions was noted. In 13 additional eyes (1%), no lesions were noted on the ICG angiogram. The studies of 16 eyes were unreadable or unobtainable.
CONCLUSIONS: There are three types of CNV that can be observed by digital ICG videoangiography. Plaques are the most common type and have a poor natural history. Focal spots or hot spots are the next most frequently seen lesion and can potentially be treated by ICG-guided laser photocoagulation. Combination lesions, in which both focal spots and plaques are present, are rare. This study of 1000 consecutive cases of eyes with occult neovascularization that were imaged with digital ICG videoangiography serves to classify the various types of neovascularization observed by this technique. Digital ICG videoangiography is an important tool in better delineating eyes with occult CNV. Future studies are necessary to validate our findings.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9003339     DOI: 10.1016/s0161-6420(96)30388-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  19 in total

1.  Radiotherapy for isolated occult subfoveal neovascularisation in age related macular degeneration: a pilot study.

Authors:  G Donati; D Soubrane; M Quaranta; G Coscas; G Soubrane
Journal:  Br J Ophthalmol       Date:  1999-06       Impact factor: 4.638

2.  [Experiences with chronic central serous chorioretinopathy treated with half-dose photodynamic therapy and verteporfin].

Authors:  M Töteberg-Harms; M Kurz-Levin; J Fleischhauer; R Windisch
Journal:  Ophthalmologe       Date:  2011-10       Impact factor: 1.059

3.  Two-Year Risk of Exudation in Eyes with Nonexudative Age-Related Macular Degeneration and Subclinical Neovascularization Detected with Swept Source Optical Coherence Tomography Angiography.

Authors:  Jin Yang; Qinqin Zhang; Elie H Motulsky; Marie Thulliez; Yingying Shi; Cancan Lyu; Luis de Sisternes; Mary K Durbin; William Feuer; Ruikang K Wang; Giovanni Gregori; Philip J Rosenfeld
Journal:  Am J Ophthalmol       Date:  2019-06-21       Impact factor: 5.258

4.  Baseline data from a multicenter, 5-year, prospective cohort study of Japanese age-related macular degeneration: an AMD2000 report.

Authors:  Akitaka Tsujikawa; Yumiko Akagi-Kurashige; Mitsuko Yuzawa; Tatsuro Ishibashi; Hideo Nakanishi; Eiji Nakatani; Satoshi Teramukai; Masanori Fukushima; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2017-12-21       Impact factor: 2.447

5.  ATP binding cassette transporter retina genotypes and age related macular degeneration: an analysis on exudative non-familial Japanese patients.

Authors:  S Kuroiwa; H Kojima; T Kikuchi; N Yoshimura
Journal:  Br J Ophthalmol       Date:  1999-05       Impact factor: 4.638

6.  Eligibility for treatment and angiographic features at the early stage of exudative age related macular degeneration.

Authors:  W M Haddad; G Coscas; G Soubrane
Journal:  Br J Ophthalmol       Date:  2002-06       Impact factor: 4.638

7.  Indocyanine green angiographic features prognostic of visual outcome in the natural course of patients with age related macular degeneration.

Authors:  A Obana; Y Gohto; M Matsumoto; T Miki; K Nishiguti
Journal:  Br J Ophthalmol       Date:  1999-04       Impact factor: 4.638

8.  Involvement of illumination in indocyanine green toxicity after its washout in the ex vivo rat retina.

Authors:  Kazuhiro Tokuda; Charles F Zorumski; Yukitoshi Izumi
Journal:  Retina       Date:  2009-03       Impact factor: 4.256

9.  Polypoidal choroidal vasculopathy in elderly Chinese patients.

Authors:  Feng Wen; Changzheng Chen; Dezheng Wu; Haitao Li
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-06-29       Impact factor: 3.117

10.  Association of clinical characteristics with disease subtypes, initial visual acuity, and visual prognosis in neovascular age-related macular degeneration.

Authors:  Yasuhiko Hirami; Michiko Mandai; Masayo Takahashi; Satoshi Teramukai; Harue Tada; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2009-09-08       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.